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Within clinical proteomics, mass spectrometry analysis of biological samples is emerging as an important high-throughput
technology, capable of producing powerful diagnostic and prognostic models and identifying important disease biomarkers. As
interest in this area grows, and the number of such proteomics datasets continues to increase, the need has developed for eﬃcient,
comprehensive, reproducible methods of mass spectrometry data analysis by both experts and nonexperts. We have designed and
implementedastand-alonesoftwaresystem,FAST-AIMS,whichseekstomeetthisneedthroughautomationofdatapreprocessing,
feature selection, classiﬁcation model generation, and performance estimation. FAST-AIMS is an eﬃcient and user-friendly stand-
alone software for predictive analysis of mass spectrometry data. The present resource review paper will describe the features and
use of the FAST-AIMS system. The system is freely available for download for noncommercial use.
Copyright © 2009 Nafeh Fananapazir et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Background
Mass spectrometry is a widely used analytical technique
capable of discriminating proteins and their postdigestion
peptide products on the basis of mass and charge. Within
the last several years, researchers have explored the use of
mass spectrometry for clinical applications in the broad
areas of early cancer detection, clinical diagnosis, and clinical
outcome prediction. Published reports indicate remarkable
potential for this technology to diagnose disease and predict
its outcome with minimally invasive testing procedures, low
cost, and—in some cases—with unprecedented accuracy. It
is expected that mass spectrometry together with other high-
throughput technologies will lead the way to personalized
medicine in the near future [1–4].
The analysis of high-throughput data such as gene
expression microarray has involved a number of statistical
challenges, the most notable of which include large number
of predictor variables and small sample sizes of typical
datasets,highinformationredundancy,limitedreproducibil-
ity, and multiple sources of noise in the data [5–7].
T h ea n a l y s i so fm a s ss p e c t r o m e t r yd a t ai n t r o d u c e sf u r t h e r
analytic challenges, requiring additional preprocessing steps
such as baseline correction of spectra, detection of peaks
corresponding to proteins and their peptide products, nor-
malization of the intensity values of these peaks, alignment
or calibration of peaks across spectra, and superimposition
ofintensityvaluescorrespondingtothesamemass-to-charge
values [4, 7–11]. Furthermore, in typical mass spectrometry
analysis, proteins are unknown a priori and identiﬁed by
mass-to-charge ratios (as opposed to the use of known
features in microarray analysis); hence, data modelling tends
to be heavily, if not exclusively, guided by the data and not by
prior biological knowledge [12].
Contrary to microarray data analysis that is nowadays
facilitated by a multitude of software systems for assisting
bothexpertsandinexperiencedanalysts[13],nosuchsystem
currently exists for mass spectrometry data that will auto-
matically enable a statistically na¨ ıve user to (i) create, from
start to ﬁnish, diagnostic/outcome prediction models, (ii)
estimate their predictive performance in future applications,
and (iii) select protein markers. Out of existing systems for
analysis of mass spectrometry data, a commercial platform
ProTS Marker by Biodesix (http://www.biodesix.com)all o w s
to manually perform the tasks mentioned above, however,
it requires signiﬁcant expertise of the user in analysis of
proteomicsdata.Therefore,thereisastrongneedforsystems
that will allow both high-quality ﬁrst-pass analyses of mass2 Advances in Bioinformatics
spectrometry data as well as enhancing work of the data
analyst.
In the present report, we describe a software system
FAST-AIMS (Fully Automated Software Tool for Artiﬁcial
Intelligence in Mass Spectrometry) which aims at providing
this functionality. In addition, given the current lack of
protocol standardization for such proteomic data analysis,
FAST-AIMS oﬀers an intuitive, stepwise sequence of analysis
in aid of developing such standardization. The system is a
stand-alone application that runs on a Windows computer
and can work with mass spectrometry data generated by
diﬀerent instruments, for example, MALDI, SELDI, LC-
MS/MS, and so forth.
2. SystemDescription
The FAST-AIMS system consists of a command-line exe-
cutable (implemented in Matlab and C) and a wizard-like
graphic user interface (implemented in Borland Delphi)
that calls the above executable with diﬀerent parameters.
Novice users should utilize a wizard-like interface, while
more experienced analysts may beneﬁt from command-
line interface for the batch analyses. FAST-AIMS runs on a
Windows computer and requires neither Matlab nor other
software to be installed. The need for Maltab is circumvented
by using Matlab Compiler that translated all relevant Matlab
code into C.
FAST-AIMS possesses an intuitive wizard-like interface
(Figure 1) with defaults provided so that users need not
be familiar with all steps of data analysis. Given a mass
spectrometry dataset as input, FAST-AIMS can automat-
ically perform one of the following tasks: (a) generate a
classiﬁcation model by optimizing the parameters of analysis
algorithms to ensure its optimal performance; (b) obtain an
unbiased estimate of the future classiﬁcation performance
of the optimized model; (c) generate a model and estimate
classiﬁcation performance in tandem; (d) apply an existing
model to a new set of samples. In the process, the system
also oﬀers the option of identifying biomarkers/features
that capture the classiﬁcation tasks of interest and can
be used to explore the underlying biological mechanisms.
All FAST-AIMS functions follow the nested N-fold cross-
validation design that allows optimization of predictive
model parameters while providing an unbiased classiﬁcation
performance estimate [13, 14]. Below, we outline the main
steps in the analysis as performed by FAST-AIMS.
(1) An opening window asks whether the user wishes
to start a new analysis or load a previously saved
analysis. In starting a new analysis, the user ﬁrst
selects the location of a mass spectrometry data
ﬁle. The system recognizes space delimited text data
ﬁles, each row of which corresponds to the intensity
values of a sample and the ﬁrst column of which
correspondstotheresponse/outcomeofeachsample.
Theusercanoptionallyspecifythelocationofthetext
ﬁle with M/Z values arranged in a column. The latter
ﬁle is used for preprocessing of mass spectrometry
data and for generation of the analysis report.
(2) The user is then asked to choose from one of the four
analysis tasks outlined above.
(3) Next, the user selects cross-validation design: N-fold
cross-validation or leave-one-out cross-validation.
(4) Then the user is asked to select whether baseline
subtraction and peak detection [15] and/or peak
alignment [16] should be performed.
(5) The user speciﬁes a normalization sequence to be
applied to the data.
(6) The classiﬁer and its parameters are selected by the
user.Thesystemusessupport-vectormachine(SVM)
classiﬁcation algorithms [17] because of their high
performance in published analyses of mass spec-
trometry data and other types of high-throughput
data, most notably gene expression arrays in which
SVMs outperformed all major pattern recognition
algorithms [18, 19].
(7) Feature/variable selection algorithms (and their
parameters) are selected by the user. The algorithms
include: using all features in the data, HITON-PC
[20], and SVM weight-based feature selection [21].
(8) The user selects a performance estimation metric:
either area under ROC curve [22], accuracy, or an
entropy-based metric relative classiﬁer information
(RCI) [23].
(9) A log ﬁle destination is speciﬁed by the user.
(10) A report ﬁle destination is speciﬁed by the user.
(11) The user clicks “Run”. If the task involves generation
of classiﬁcation model and/or performance estima-
tion, the system considers each permutation of the
classiﬁer and feature selection algorithm parameters.
Some steps can be performed on each spectrum indepen-
dently (e.g., peak detection, baseline subtraction, and some
normalization methods). All steps that require consideration
of multiple spectra (e.g., peak alignment, classiﬁcation, and
feature selection) are performed on each training set of
the data to ensure unbiased estimates of the classiﬁcation
performance.
3. Discussion
In our prior work [24], we have evaluated an early prototype
version of the FAST-AIMS system using an SELDI mass
spectrometry prostate cancer dataset with 162 spectra. The
evaluation revealed that the system achieves classiﬁcation
performance comparable to the human expert statistician
and superior to the previously published analysis in liter-
ature. It took users on average 30 minutes to familiarize
with functionality of the system and 19 hours to build the
ﬁnal model, while an expert statistician spent 7 hours for
this task. Application of the model to new samples took
less than 5 minutes. In general, depending on the dataset
characteristics and selected data analysis options, it can take
FAST-AIMS from 5 minutes to several days to analyze aAdvances in Bioinformatics 3
Figure 1: Screenshot of the FAST-AIMS system. The left part of the screen contains options for the current analysis step (variable (M/Z)
selection). The summary of the entire analysis project is shown in the right part of the screen.
dataset (i.e., build the ﬁnal model). However, a basic ﬁrst-
pass analysis can be conducted within 2–3 hours for a dataset
with 200 samples and 60.000 features. Compared to the early
prototype version of FAST-AIMS used in [24], the current
system has additional functionality (e.g., more performance
estimation metrics, ability to output report in HTML ﬁle,
automatically updated project summary and estimation of
complexity of the analysis, built-in help system) and stable
software code ready for the public release. Furthermore, the
present report provides FAST-AIMS to the community for
the ﬁrst time.
The FAST-AIMS system is designed for mass spectrom-
etry data analysis and inherits challenges of using that
technology. For example, given a mass spectrometry dataset
a system identiﬁes biomarkers/features that correspond to
anonymous peak intensities and may have little signiﬁcance
for the clinical practice [25, 26]. Any potentially interesting
peak would have to be examined using an MS/MS system
and the ﬁndings have to be conﬁrmed by a quantitative
proteomics approach [27, 28]. However, we emphasize that
FAST-AIMS can be universally applied to various MS and
tandem MS measurement technologies and does not require
use of speciﬁc proteomic platforms such as SELDI or
MALDI.
Finally, we believe that recent eﬀorts of the cancer
Biomedical Informatics Grid (caBIG) would allow improv-
ing the future versions of the FAST-AIMS system. For
example, FAST-AIMS can incorporate proteomics related
data standards such as mzData (for capturing peak list
information) and mzXML (for storage and exchange of
mass spectroscopy data) which would make the system more
interoperable and would allow obtaining data directly from
the proteomics instruments.
4. Conclusions
In this report, we have presented a software system FAST-
AIMS for automated predictive analysis of mass spectrome-
try data. FAST-AIMS is a stand-alone Windows application
with an intuitive wizard-like interface that guides the user
through diﬀerent steps of data analysis. The system is
freely available for download for noncommercial use from
http://www.dsl-lab.org/FAST-AIMS.
Authors’ Contributions. All authors conceived and designed
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AS drafted the paper. All authors read, revised, and approved
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